Edgen Stock·Dec 12 2025, 01:45Back
Back
Intuitive Surgical Navigates GLP-1 Drug Headwinds
Edgen Stock·Dec 12 2025, 01:45
[1] Lilly's next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trial - Reuters[2] Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges - BioSpace[3] Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial - cnbc.com
Features
Resources
© 2026 Finture Development Limited. All rights reserved